Tags

Type your tag names separated by a space and hit enter

BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Bone Marrow Transplant. 1996 Oct; 18(4):693-8.BM

Abstract

Since 1984 we have autografted a total of 60 patients with AML in second complete remission (CR) utilizing the BAVC (BCNU, amsacrine, vepesid, cytosine-arabinoside) conditioning regimen and unpurged marrow. Projected disease-free survival (DFS) probability in 42% at 10 years. Autografting was performed at a median interval of 2 months (range 1-13) from second CR. The median duration of first CR was 14 months (range 1-43) and lasted < or = 12 months in 27/60 patients. Three early deaths (5%) occurred, 30 patients relapsed after a median of 6 months from transplant (range 2-28) and, of the remaining 27 patients, 26 are in continuous CR (CCR) after a median follow up of 60 months (range 6-122), while the last patient committed suicide 7 years after ABMT when she was still in CCR. A first CR duration > 12 months is correlated with a significantly better overall survival probability (61 vs 25%, P = 0.02), while no factors influence DFS. Outcome of patients who relapsed after autografting has been analyzed separately; a longer overall survival after relapse is correlated with a longer duration of the second CR (62% at 34 months for patients who relapsed after > 12 months from the autograft vs 5% for the others, P = 0.001). These results confirm that AML patients autografted in second CR with BAVC regimen and unpurged marrow have the possibility of becoming long-term DFS and can therefore be cured.

Authors+Show Affiliations

Department of Human Biopatology, University La Sapienza, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8899182

Citation

Meloni, G, et al. "BAVC Regimen and Autograft for Acute Myelogenous Leukemia in Second Complete Remission." Bone Marrow Transplantation, vol. 18, no. 4, 1996, pp. 693-8.
Meloni G, Vignetti M, Avvisati G, et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant. 1996;18(4):693-8.
Meloni, G., Vignetti, M., Avvisati, G., Capria, S., Micozzi, A., Giona, F., & Mandelli, F. (1996). BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplantation, 18(4), 693-8.
Meloni G, et al. BAVC Regimen and Autograft for Acute Myelogenous Leukemia in Second Complete Remission. Bone Marrow Transplant. 1996;18(4):693-8. PubMed PMID: 8899182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. AU - Meloni,G, AU - Vignetti,M, AU - Avvisati,G, AU - Capria,S, AU - Micozzi,A, AU - Giona,F, AU - Mandelli,F, PY - 1996/10/1/pubmed PY - 1996/10/1/medline PY - 1996/10/1/entrez SP - 693 EP - 8 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 18 IS - 4 N2 - Since 1984 we have autografted a total of 60 patients with AML in second complete remission (CR) utilizing the BAVC (BCNU, amsacrine, vepesid, cytosine-arabinoside) conditioning regimen and unpurged marrow. Projected disease-free survival (DFS) probability in 42% at 10 years. Autografting was performed at a median interval of 2 months (range 1-13) from second CR. The median duration of first CR was 14 months (range 1-43) and lasted < or = 12 months in 27/60 patients. Three early deaths (5%) occurred, 30 patients relapsed after a median of 6 months from transplant (range 2-28) and, of the remaining 27 patients, 26 are in continuous CR (CCR) after a median follow up of 60 months (range 6-122), while the last patient committed suicide 7 years after ABMT when she was still in CCR. A first CR duration > 12 months is correlated with a significantly better overall survival probability (61 vs 25%, P = 0.02), while no factors influence DFS. Outcome of patients who relapsed after autografting has been analyzed separately; a longer overall survival after relapse is correlated with a longer duration of the second CR (62% at 34 months for patients who relapsed after > 12 months from the autograft vs 5% for the others, P = 0.001). These results confirm that AML patients autografted in second CR with BAVC regimen and unpurged marrow have the possibility of becoming long-term DFS and can therefore be cured. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/8899182/BAVC_regimen_and_autograft_for_acute_myelogenous_leukemia_in_second_complete_remission_ L2 - http://www.diseaseinfosearch.org/result/204 DB - PRIME DP - Unbound Medicine ER -